Can You Get GLP-1 Without BMI Requirements: Eligibility Truth

Introduction

There’s a real answer and an evasive answer to this question. The real answer in 2026 is that GLP-1 medications have specific FDA-approved BMI thresholds: 30 or above, or 27 or above with at least one weight-related comorbidity (hypertension, type 2 diabetes, sleep apnea, dyslipidemia, cardiovascular disease). Off-label prescribing happens but reputable telehealth platforms generally won’t write GLP-1 for someone with a BMI of 23 just because they want to lose 10 pounds. They will sometimes prescribe at BMI 25-27 with a comorbidity that a clinician documents.

The evasive answer is the version some gray-market sellers give: any BMI is fine. That’s marketing, not medicine. Off-label prescribing is legal but requires a clinician to document a justification, and most US-licensed clinicians won’t write GLP-1 for a normal-weight patient without specific clinical reasoning.

This guide walks through the actual FDA labels, what off-label means in practice, which conditions count as a comorbidity, and how flexibility actually works in 2026.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Are the FDA-approved BMI Requirements for GLP-1?

The FDA-approved indications for weight management are specific and consistent across the three main GLP-1 drugs (Wegovy®/semaglutide, Zepbound®/tirzepatide, Saxenda®/liraglutide). The adult thresholds are:

Quick Answer: FDA-approved BMI thresholds for Wegovy and Zepbound: 30+ (obesity), or 27+ with at least one weight-related comorbidity

• BMI 30 or above (obesity), OR
• BMI 27 or above (overweight) with at least one weight-related comorbid condition

Saxenda is also FDA-approved for adolescents 12 and older with body weight above 60 kg and BMI in the 95th percentile or higher. Wegovy was approved for adolescents 12 and older in late 2022 with the same BMI percentile threshold.

These thresholds match the populations studied in the phase 3 trials. SURMOUNT-1 enrolled BMI 30+ or 27+ with comorbidity. STEP 1 (Wilding et al. 2021 NEJM) enrolled the same population. Trying to extrapolate efficacy to a BMI 23 population is leaving the evidence base.

What Counts as a Weight-related Comorbidity?

The most commonly accepted comorbidities for prescribing at BMI 27-29 include:

• Hypertension (high blood pressure)
• Type 2 diabetes
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Atherosclerotic cardiovascular disease
• Non-alcoholic fatty liver disease (MASLD/MASH)
• Polycystic ovary syndrome (PCOS)
• Severe osteoarthritis of weight-bearing joints
• Pre-diabetes (A1C 5.7-6.4%)

Insurance plans use a stricter list than telehealth cash-pay programs. Insurance often requires hypertension, diabetes, or sleep apnea specifically. Cash-pay platforms tend to accept the broader list above.

Does Any Legitimate Telehealth Provider Prescribe Below BMI 27?

A few do for specific clinical reasons, but it’s the minority. Conditions where below-threshold prescribing is sometimes considered:

• A patient with PCOS and insulin resistance at BMI 26
• A patient with type 2 diabetes well controlled but with weight rebound concerns
• A patient post-weight-loss-surgery rebounding from BMI 22 back upward

Outside these scenarios, prescribing below BMI 27 generally falls outside accepted clinical practice and most reputable platforms won’t do it. If a site is willing to prescribe at BMI 22 with no comorbidity, that’s a warning, not a feature.

What If My BMI Is Just Under 27 but I Have a Comorbidity?

This is the most common gray zone. BMI 26.5 with hypertension is a reasonable clinical case for off-label prescribing because the patient is medically similar to the trial population. Some platforms accept this, some don’t.

Clinicians document the off-label justification in the chart: BMI 26.5, hypertension on lisinopril, A1C 5.9%, goal is cardiovascular risk reduction and pre-diabetes reversal. That’s a defensible off-label prescription. The same prescription at BMI 24 with no comorbidities is harder to justify.

TrimRx’s free assessment quiz captures BMI, comorbidities, and meds, then routes to a licensed clinician who decides whether the case qualifies.

What About People Just Under Threshold but with Strong Family History?

Family history alone usually isn’t enough to prescribe below threshold. The FDA labels don’t include family history of obesity or diabetes as a qualifying comorbidity. A clinician might consider it in combination with other factors (BMI 26.8, family history of early type 2 diabetes, fasting glucose 100, A1C 5.7), but family history without other findings rarely changes the prescribing decision.

The clinical lever is your own metabolic state. If your A1C is 5.7-6.4%, that’s pre-diabetes and counts. If your fasting glucose is 100-125, that’s pre-diabetes and counts. If your blood pressure is 130/85+ on two readings, that’s hypertension and counts.

Are BMI Rules Different for Compounded vs Brand-name?

Legally, no. Compounded GLP-1 is held to the same clinical standards because the prescribing clinician is the gatekeeper. In practice, cash-pay compounded programs have more flexibility because they aren’t constrained by insurance prior authorization criteria.

The flexibility tends to show up at the BMI 26-29 range with mild comorbidities. Insurance will often deny prior auth there. Cash-pay compounded programs often approve. Below BMI 25 with no comorbidity, reputable platforms generally decline regardless of payment method.

Key Takeaway: SURMOUNT-1 (Jastreboff et al. 2022 NEJM) enrolled adults with BMI 30+ or 27+ with comorbidity, the same threshold the FDA approved

What About Athletes with High Muscle Mass and BMI 28?

This is the legitimate edge case where BMI overstates body fat. Bodybuilders and other muscular athletes can have BMI 28-30 with low body fat and no metabolic concerns. They don’t need GLP-1 for weight loss.

A clinician reviewing intake would catch this. If a 35-year-old male reports BMI 28, weight 195 lb, body composition tracking, and no metabolic concerns, the right answer is usually not GLP-1. The drug treats metabolic dysregulation, not BMI numbers in isolation.

Reputable telehealth platforms screen for this. Gray-market sellers don’t.

What If I Want GLP-1 for Cosmetic Weight Loss at BMI 24?

Most US-licensed clinicians won’t write GLP-1 below BMI 25 without a clinical reason. The risk-benefit math doesn’t favor it. Side effects (nausea, vomiting, gastroparesis risk, gallbladder issues, muscle mass loss) are the same. The benefit (cardiovascular risk reduction, diabetes prevention) is less because the baseline risk is lower.

The cosmetic-weight-loss request at BMI 24 became common enough in 2023-2024 that the American Society of Bariatric Physicians and Endocrine Society both published position statements discouraging it. The drugs were studied in people with metabolic disease. Using them in metabolically healthy people is leaving the evidence and adding side-effect risk for limited benefit.

How Does Insurance Handle BMI Requirements?

Insurance prior authorization is the strictest gate. Typical requirements:

• BMI 30+ documented, OR BMI 27+ with at least one specific comorbidity (usually hypertension, type 2 diabetes, or sleep apnea, with the others sometimes accepted)
• Documented weight management attempts (diet, exercise) over 3-6 months
• A1C and lipid panel within the past 12 months
• Sometimes a documented BMI trend showing weight increase or plateau

Insurance is the slow path. Cash-pay through telehealth typically skips all of this except the BMI check.

What About Post-bariatric-surgery Patients?

Patients who have had bariatric surgery (Roux-en-Y, sleeve gastrectomy) sometimes need GLP-1 for weight regain or to support weight loss in the first place. Their pre-surgical BMI usually qualifies them, and post-surgical regain is a recognized clinical scenario where GLP-1 is appropriate even if current BMI is in a lower range.

The clinical documentation matters. “Status post sleeve gastrectomy 2019, peak BMI 42, current BMI 28 with 8 kg regain over 18 months” is a clearly defensible off-label or off-threshold case.

Bottom line: Comorbidities that count: hypertension, type 2 diabetes, dyslipidemia, sleep apnea, cardiovascular disease, fatty liver, PCOS, osteoarthritis

FAQ

Can I Get GLP-1 at BMI 26?

Sometimes, with a documented weight-related comorbidity such as hypertension, type 2 diabetes, sleep apnea, or PCOS. The FDA threshold is 27 with comorbidity, so 26 is one point below and requires off-label justification.

What If My BMI Is 24 but I Want to Lose 15 Pounds?

Reputable telehealth providers generally won’t prescribe GLP-1 below BMI 25 without a specific clinical reason. The medication is studied and approved for overweight and obesity, not cosmetic weight loss in metabolically healthy people.

Does PCOS Qualify as a Comorbidity at BMI 27?

In most cash-pay telehealth programs, yes. PCOS with insulin resistance is a recognized weight-related condition. Insurance plans vary on whether they accept PCOS specifically.

What About Pre-diabetes (A1C 5.7-6.4%) at BMI 26?

Many clinicians will write GLP-1 in this scenario, framed as diabetes prevention. The DPP showed 58% diabetes risk reduction with lifestyle, and adding semaglutide adds further metabolic improvement. The off-label case is well-supported.

Does Measuring BMI From Waist Circumference Change Anything?

No, BMI is calculated from weight and height. Waist circumference is sometimes used as an additional risk marker (over 35 inches in women, 40 inches in men), and it can support an off-label case at BMI 26-27 by documenting central adiposity.

Is BMI an Outdated Metric for GLP-1 Eligibility?

There’s an active debate among obesity medicine specialists. BMI doesn’t capture body composition, ethnicity-specific risk, or metabolic status well. But it’s still the FDA-approved threshold, and almost all trial data is structured around it. A move toward body-composition-based eligibility is happening slowly.

Can I Appeal an Insurance Denial If I’m Just Under BMI Threshold?

Yes, with documented comorbidities, A1C, blood pressure trends, and a letter of medical necessity from the prescribing clinician. Appeals at BMI 27-29 with a comorbidity are sometimes successful. Below BMI 27, appeals rarely succeed.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.